ArticleFrontiers in reproductive health2025
Precision prediction of hyperhomocysteinemia development in perimenopausal women using LASSO regression.
Article in Frontiers in reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperhomocysteinemia (HHcy) is associated with an increased risk of cardiovascular diseases, particularly in perimenopausal women, who are more susceptible to metabolic disorders due to declining estrogen levels. This study aimed to identify risk factors and develop a predictive model for HHcy in this population. Methods: A retrospective study included 687 perimenopausal women, divided into a training set (481) and an internal validation set (206). Demographic characteristics, pregnancy-related factors, lifestyles, and diet information were collected by questionnaire. 63 perimenopausal women hospitalized from March to June 2025 were selected as the external validation set. The least absolute shrinkage and selection operator (LASSO) regression was used to select variables. The logistic regression model was developed to predict HHcy risk, with results visualized using a nomogram. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: 137 of 687 (19.94%) perimenopausal women had HHcy. Through Lasso regression and multifactor logistic regression, 4 predictors were identified, including egg consumption frequency, LDL, TP, and CysC for constructing the nomogram model. The AUC of the training set was 0.765 (95% CI = 0.708-0.822), for the internal validation set was 0.854 (95% CI = 0.781-0.928), and for the external validation set was 0.776 (95% CI = 0.603-0.949), indicating good predictive performance of the model. Conclusion: The nomogram demonstrated high predictive accuracy and clinical utility, providing a potential tool for HHcy risk prediction and selection of treatment strategies in perimenopausal women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.